BR9913748A - Composition, use of composition method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit - Google Patents
Composition, use of composition method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kitInfo
- Publication number
- BR9913748A BR9913748A BR9913748-8A BR9913748A BR9913748A BR 9913748 A BR9913748 A BR 9913748A BR 9913748 A BR9913748 A BR 9913748A BR 9913748 A BR9913748 A BR 9913748A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- kit
- improving
- treatment
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSIçãO, USO DA COMPOSIçãO MéTODO PARA O TRATAMENTO DE DISTúRBIOS MEDIADOS POR 5-HT, MéTODO DE MELHORIA DO INìCIO DA AçãO TERAPêUTICA, FORMULAçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DA COMPOSIçãO, E, KIT". A invenção refere-se a uma composição compreendendo um primeiro componente (a) que é hidrogeno-(2R,3R)-tartarato de (R)-3-N,N-diciclo-butil-amino-8-fluoro-3,4-di-hidro-2H-1-benzopiran-5- carboxamida mono-hidratado e um segundo componente (b) que é paroxetina, na forma de sua base livre, ou de um seu solvato e/ou sal farmaceuticamente aceitável, à sua preparação, às formulações farmacêuticas contendo a citada composição, ao uso da mesma e a um processo de tratamento de distúrbios afetivos, tais como distúrbios de humor e distúrbios de ansiedade, com a citada composição, bem como com a um kit contendo a citada composição."COMPOSITION, USE OF COMPOSITION METHOD FOR TREATING DISTURBES MEDIATED BY 5-HT, METHOD OF IMPROVING THE START OF THERAPEUTIC ACTION, PHARMACEUTICAL FORMULATION, PROCESS FOR THE PREPARATION OF COMPOSITION, AND, KIT". The invention relates to a composition comprising a first component (a) which is (R) -3-N, N-dicyclo-butyl-amino-8-fluoro-3,4 hydrogen (2R, 3R) -dihydro-2H-1-benzopyran-5-carboxamide monohydrate and a second component (b) which is paroxetine, in the form of its free base, or a solvate and / or pharmaceutically acceptable salt thereof, to its preparation , to pharmaceutical formulations containing said composition, to the use of it and to a process of treatment of affective disorders, such as mood disorders and anxiety disorders, with said composition, as well as with a kit containing said composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803156A SE9803156D0 (en) | 1998-09-16 | 1998-09-16 | A new composition |
| PCT/SE1999/001597 WO2000015218A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9913748A true BR9913748A (en) | 2001-07-10 |
Family
ID=20412627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9913748-8A BR9913748A (en) | 1998-09-16 | 1999-09-13 | Composition, use of composition method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1128825A1 (en) |
| JP (1) | JP2002524508A (en) |
| KR (1) | KR20010099647A (en) |
| CN (1) | CN1317964A (en) |
| AR (1) | AR021808A1 (en) |
| AU (1) | AU6378099A (en) |
| BR (1) | BR9913748A (en) |
| CA (1) | CA2342341A1 (en) |
| CZ (1) | CZ2001961A3 (en) |
| EE (1) | EE200100157A (en) |
| HU (1) | HUP0103544A3 (en) |
| ID (1) | ID28785A (en) |
| IL (1) | IL141519A0 (en) |
| IS (1) | IS5879A (en) |
| NO (1) | NO20011312L (en) |
| PL (1) | PL346763A1 (en) |
| SE (1) | SE9803156D0 (en) |
| SK (1) | SK3262001A3 (en) |
| TR (1) | TR200100779T2 (en) |
| WO (1) | WO2000015218A1 (en) |
| ZA (1) | ZA200101946B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03003264A (en) | 2000-10-13 | 2003-06-06 | Neurosearch As | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance. |
| US20090036488A1 (en) * | 2005-03-04 | 2009-02-05 | Tokyo Medical And Dental University | Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501567D0 (en) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
-
1998
- 1998-09-16 SE SE9803156A patent/SE9803156D0/en unknown
-
1999
- 1999-09-13 AU AU63780/99A patent/AU6378099A/en not_active Abandoned
- 1999-09-13 PL PL99346763A patent/PL346763A1/en unknown
- 1999-09-13 IL IL14151999A patent/IL141519A0/en unknown
- 1999-09-13 WO PCT/SE1999/001597 patent/WO2000015218A1/en not_active Application Discontinuation
- 1999-09-13 KR KR1020017003337A patent/KR20010099647A/en not_active Application Discontinuation
- 1999-09-13 EP EP99951319A patent/EP1128825A1/en not_active Withdrawn
- 1999-09-13 JP JP2000569802A patent/JP2002524508A/en active Pending
- 1999-09-13 CN CN99811010A patent/CN1317964A/en active Pending
- 1999-09-13 CA CA002342341A patent/CA2342341A1/en not_active Abandoned
- 1999-09-13 TR TR2001/00779T patent/TR200100779T2/en unknown
- 1999-09-13 HU HU0103544A patent/HUP0103544A3/en unknown
- 1999-09-13 CZ CZ2001961A patent/CZ2001961A3/en unknown
- 1999-09-13 ID IDW20010581A patent/ID28785A/en unknown
- 1999-09-13 BR BR9913748-8A patent/BR9913748A/en not_active Application Discontinuation
- 1999-09-13 SK SK326-2001A patent/SK3262001A3/en unknown
- 1999-09-13 EE EEP200100157A patent/EE200100157A/en unknown
- 1999-09-15 AR ARP990104626A patent/AR021808A1/en not_active Application Discontinuation
-
2001
- 2001-03-07 IS IS5879A patent/IS5879A/en unknown
- 2001-03-08 ZA ZA200101946A patent/ZA200101946B/en unknown
- 2001-03-15 NO NO20011312A patent/NO20011312L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2342341A1 (en) | 2000-03-23 |
| AU6378099A (en) | 2000-04-03 |
| TR200100779T2 (en) | 2001-10-22 |
| CN1317964A (en) | 2001-10-17 |
| NO20011312D0 (en) | 2001-03-15 |
| SE9803156D0 (en) | 1998-09-16 |
| EP1128825A1 (en) | 2001-09-05 |
| ID28785A (en) | 2001-07-05 |
| EE200100157A (en) | 2002-08-15 |
| HUP0103544A3 (en) | 2003-12-29 |
| ZA200101946B (en) | 2002-06-10 |
| JP2002524508A (en) | 2002-08-06 |
| IS5879A (en) | 2001-03-07 |
| WO2000015218A1 (en) | 2000-03-23 |
| AR021808A1 (en) | 2002-08-07 |
| KR20010099647A (en) | 2001-11-09 |
| SK3262001A3 (en) | 2001-08-06 |
| CZ2001961A3 (en) | 2001-08-15 |
| HUP0103544A2 (en) | 2002-05-29 |
| IL141519A0 (en) | 2002-03-10 |
| PL346763A1 (en) | 2002-02-25 |
| NO20011312L (en) | 2001-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3553083B2 (en) | Peripherally active antihyperalgesic opiates | |
| BR0113042A (en) | Compound of the formula or a physiologically acceptable solvate thereof, use thereof, pharmaceutical composition, pharmaceutical formulation, method for treating a human or animal subject with an inflammatory and / or allergic condition, and process for preparing a compound or solvate thereof | |
| BR0312216A (en) | Compound, process for producing a compound, pharmaceutical composition, use of the compound, method for treating a subject suffering from a disease or condition and product combination | |
| BR0012488A (en) | Pharmaceutical composition, methods for improving the absorption rate of one or more than one pharmaceutically active agent in mammals, for improving the onset of the therapeutic benefit of one or more than one pharmaceutically active agent in mammals, for inhibiting gastroirritation in a mammal. , and for treating mammals requiring treatment provided by one or more than one pharmaceutically active agent, and, process for preparing a pharmaceutical composition. | |
| BR9812088A (en) | Combination of components, use of this, processes for its preparation, for the treatment of affective disorders, for the treatment of depression, and to improve the beginning of therapeutic action, pharmaceutical formulation, and, kit | |
| BR0015974A (en) | Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound | |
| BRPI0410786A (en) | composition, use, and method of treating a mood disorder in a patient | |
| BR0317747A (en) | Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment | |
| BR0308816A (en) | Thiazolidine-4-carbonitriles and analogs and their uses as dipeptide peptide inhibitors | |
| BR0207694A (en) | Compound or a physiologically functional salt, solvate or derivative thereof, method for the prophylaxis or treatment of a clinical condition in a mammal, pharmaceutical formulation, combination, use of a pharmaceutically acceptable salt, solvate or derivative thereof, process for the preparation of a compound or a physiologically functional salt, solvate or derivative thereof, and intermediates | |
| BRPI0314308B8 (en) | opioid antagonists, their uses, and pharmaceutical composition | |
| BR0108600A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease | |
| BR0207802A (en) | Use of inverse gabaa agonists in combination with nicotine receptor partial agonists, estrogens, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders. | |
| BR0214967A (en) | Compound, pharmaceutically acceptable salt, process for preparing a compound, pharmaceutical composition, use of a compound and method of treating a patient disorder | |
| BR0112661A (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation | |
| SE9501567D0 (en) | A new combination | |
| BR9812236A (en) | Combination of components, use of this, processes for its preparation, for the treatment of affective disorders, for the treatment of depression, and to improve the beginning of therapeutic action, pharmaceutical formulation, and, kit | |
| BRPI0407253A (en) | Heterocyclyl-3-sulfonylindazoles as ligands 5-hydroxytryptamine-6 process for their preparation, their uses in the preparation of a pharmaceutical composition and a pharmaceutical composition comprising said compounds | |
| BR0109672A (en) | Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal | |
| BR0308133A (en) | Crystalline polymorphic form of irinotecan hydrochloride | |
| BR9810773A (en) | Use of a long-acting local anesthetic ingredient, pharmaceutical composition, use of a local anesthetic, and, kit | |
| BRPI0414347A (en) | combination comprising an alpha-2-delta ligand and an ssri and / or snri for treatment of depression and anxiety disorders | |
| BRPI0411665A (en) | use of agomelatine or a pharmaceutically acceptable salt thereof, pharmaceutical composition or kit, and methods for treating diseases or disorders responsive to a serotonin reuptake inhibitor and for increasing and / or providing a faster onset of the therapeutic effect of an inhibitor of serotonin reuptake | |
| BR0206300A (en) | pharmaceutical composition to treat urinary disorder in a mammal and use | |
| RU2005123808A (en) | CARBOSTIRYL DERIVATIVES AND SEROTONIN REVERSE INHIBITORS FOR TREATMENT OF EMOTIONAL DISORDERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |